ObjectiveTo understand the current status, research hotspots, and future trends in the field of retinoblastoma (RB). MethodsUsing the Web of Science Core Collection SSCI and SCI-Expanded as data sources, relevant RB literature from January 2015 to November 2024 was retrieved. The bibliometric analysis software CiteSpace 6.2.R6 was employed to perform visual analyses of countries/regions, institutions, journals, authors, co-cited references, and keywords. ResultsA total of 5 042 relevant publications were identified. Annual publication numbers in this field consistently exceeded 400, peaking at 565 in 2021. The United States contributed the highest number of publications, with 1 600 articles (31.73%). Among institutions, Harvard University ranked first with 167 publications (3.31%). Abramson DH of Memorial Sloan Kettering Cancer Center published the most papers (75). Nature (United Kingdom) received the highest citation count (2 349). The highest betweenness centrality was observed for the United States (0.14) among countries/regions, Shanghai Jiao Tong University (0.21) among institutions, and Berry JL of Children’s Hospital Los Angeles (0.21) at the author level. Co-citation and keyword analyses revealed that RB research hotspots are shifting from a focus on basic molecular mechanisms, such as the cell cycle and RB protein, toward advanced therapeutic strategies, such as intra-arterial chemotherapy and nanoparticle-based drug delivery. Emerging keywords such as complexity, chemoresistance and carboplatin indicate that future studies will focus on optimising diagnosis and treatment. ConclusionsFrom 2015 to 2024, RB research displayed a sustained growth trend, with the United States and its institutions and scholars contributing the most publications. The research focus has shifted from the exploration of molecular mechanisms to the optimization of precise treatment strategies, among which the application of nanotechnology and the resolution of drug resistance mechanisms will become key breakthrough directions.
ObjectiveTo analyze the research hotspots and development trends of core outcome set (COS) from 2015 to 2024, providing a reference for future research in this field. MethodsWe retrieved literature on COS research from the Web of Science Core Collection and CNKI spanning January 1, 2015 to December 31, 2024. We extracted and organized data on the number of publications, journals, citation frequency, and keywords using Excel 2021. We performed keyword clustering analysis using VOSviewer 1.6.13 and generated strategic coordinate maps using Bibliometrix 3.13 in R 4.3.1. ResultsWe included a total of 1 288 studies, comprising 1 085 English publications and 203 Chinese publications. From 2015 to 2024, the number of COS publications showed a steady increase. English journals covered a wide range of fields, while Chinese journals were mainly focused on traditional Chinese medicine. High-impact articles primarily focused on COS methodology. Chinese literature mainly concentrated on the application of COS in traditional Chinese medicine, while English literature focused on child health, Delphi surveys, quality of life, and pain. The results of the strategic coordinate map showed that research on acupuncture core outcome indicators, qualitative studies of surgical COS, and Delphi-based COS for quality of life in patients with rheumatoid diseases were relatively weak, with significant room for improvement. ConclusionOver the past decade, COS research has shown a steady growth trend and has gradually become an important tool for improving the standardization and scientific rigor of clinical research. As COS research continues to expand, there is increasing overlap in the scope and findings of different studies. Future research could incorporate umbrella and basket study designs to optimize resource utilization and promote the application of COS in clinical practice.